北京高盟新材料股份有限公司 投资者关系活动记录表 编号：2025-003 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 ■其他 电话会 参与单位名称及 人员姓名 华福证券：魏征宇 时间 2025 年 8 月 25 日，10:00-11:00 地点 公司会议室（电话会） 上市公司接待人 员姓名 副总经理、董事会秘书：史向前 投资者关系活动 主要内容介绍 公司与投资者进行了充分的交流与沟通，严格按照相关规 定，保证信息披露的真实、准确、完整、及时、公平性，没有 出现未公开重大信息泄露等情况。沟通主要内容如下：公司副 总经理、董事会秘书史向前首先就公司 2025 年半年度经营情 况、未来发展战略等做了介绍。公司 2025 年经营指导思想为 "战略引领，创新驱动国际化；项目攻坚，提质上量增人效"， 并重点介绍了公司未来发展战略，即领先发展复合粘接材料、 提升发展交通功能材料、加快发展电气功能材料、突破发展光 学显示材料。 1、公司在"复合粘接材料"领域提到高固含功能型粘合 剂、药包用粘合剂、聚酯通用型无溶剂粘合剂等产品销售表现 良好。这些明星产品目 ...

Core Viewpoint - Peijia Medical Limited reported a total revenue of RMB 353 million for the six months ending June 30, 2025, representing a 17.3% increase compared to the same period in 2024, with stable revenue contributions from TAVR and neurointerventional products [1] Financial Summary - The sales revenue from TAVR-related products increased by 24.0% to RMB 162 million, driven by an enhanced market share in China's TAVR market and a shift towards newly launched high-end products [2] - Neurointerventional products saw a 12.2% increase in sales revenue to RMB 192 million, supported by deeper market penetration of existing products and the successful launch of the YonFlow® stent [2] - The overall operating loss narrowed by 19.4% to RMB 68.32 million, with core business net loss significantly reduced by 52.4% to RMB 30.72 million [2] Cost Control and Efficiency - The TAVR business achieved commercial profitability for the first time, generating a profit of RMB 29.09 million, with sales and distribution expenses decreasing by 8.3% to RMB 100 million [4] - R&D expenses for the TAVR division decreased by 17.2% to RMB 54.2 million, primarily due to the completion of major clinical trials [4] - The management expenses slightly increased by 2.8% to RMB 50.98 million, mainly due to depreciation costs of a new headquarters [4] Innovation and Product Development - Three key in-development products are entering the registration application phase, including the TaurusTrio™ TAVR system, TaurusNXT® TAVR system, and GeminiOne® TEER system, with expected approvals between late 2025 and mid-2026 [5] - The DCwire® microguidewire and YonFlow® stent are highlighted as strong performers in the neurointerventional segment, with the former's sales revenue increasing nearly 140% [9] - The company is preparing for the market launch of the TaurusTrio™, which is expected to significantly enhance its competitive position in the AR valve market [5] Operational Efficiency - The neurointerventional division's profit increased by 42.4% to RMB 40.9 million, supported by effective cost control and operational efficiency measures [11] - The company has successfully integrated lean production and supply chain management to mitigate revenue pressures from centralized procurement [11] - The overall strategy emphasizes innovation-driven growth, operational efficiency, and maintaining market leadership in cardiovascular disease treatments [11]

江中药业 20250822 摘要 江中药业 2025 年上半年营收增长 5.8%，经营性现金流同比上升 29.07%至 6.52 亿元。OTC 业务同比下降约 10%至 15.5 亿元，健康 消费品业务增长 17.35%至 2.28 亿元，处方药业务增长 7.44%至 3.6 亿元。 公司聚焦 OTC、健康消费品和处方药三大业务，通过品牌和创新驱动高 质量发展。OTC 业务巩固优势品类，拓展新赛道；健康消费品深化组织 重塑，加强自营能力；处方药则围绕特定人群和领域挖掘潜力。 江中药业积极推进智能制造，通过精益管理提升生产效率，推动数字化 转型升级。金匠产业园现代工厂建设稳步推进，江东影片智慧代煎中心 引入信息化管理系统，济生制药入选江西省先进级智能工厂。 公司加强营销数字化建设，推进营销驾驶舱建设，引进 AI 工具优化数据 处理，加强数据监测与分析，并与下游终端开展数字化合作。同时，提 升项目管理能力与效率，全面推进子公司核心业务领域的数字化转型升 级。 江中药业强化人才体系建设，构建全周期管理机制，整合组织资源，优 化全责体系，并持续引进科研人才和开展专项培训。激励机制向科研人 才倾斜，第二期激励计划覆盖 ...

事件：公司披露2025 年半年度业绩，25H1 公司实现营收2.04 亿元同比+8.63%；归母净利润0.35 亿元， 同比+22.64%；扣非归母净利润0.35 亿元，同比+27.73%。其中，25Q2 营收1.02 亿元，同比+6.85%；归 母净利润0.18 亿元，同比+11.04%；扣非归母净利润0.17 亿元，同比+14.15%。 盈利预测及投资建议：公司凭借长期积累，已形成稳定的客户群。在经济弱复苏的背景下，公司经营韧 性显著，产品质量与品牌价值保持业内龙头地位。我们预计25-27 年实现营收4.91/5.94/7.17 亿元，归母 净利润0.8/0.99/1.20 亿元，对应PE 分别为34.33/27.90/23.10x，维持推荐评级。 公司坚持创新驱动，持续深化产品布局。分产品来看，25H1 酱汁类调味料/粉体类调味料/食品添加剂 分别实现营业收入1.46 亿元/0.45 亿元/0.01 亿元，分别同比-1.51%/+20.13%/+45.29%。单 25Q2 公司酱 汁类调味料/粉体类调味料/食品添加剂营收分别为 0.69 亿元/0.22 亿元/0.0074亿元，分别同 比-8.23%/+ ...

证券代码：603976 证券简称：正川股份 公告编号：2025-053 债券代码：113624 债券简称：正川转债 重庆正川医药包装材料股份有限公司 关于 2025 年度"提质增效重回报"行动方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重庆正川医药包装材料股份有限公司（以下简称"公司"）为深入贯彻落实 国务院《关于进一步提高上市公司质量的意见》《关于加强监管防范风险推动资 本市场高质量发展的若干意见》要求，积极响应上海证券交易所《关于开展沪市 公司"提质增效重回报"专项行动倡议》，推动公司向高质量发展，切实保障和 维护投资者合法权益，进一步增强投资者信心，结合公司实际，制定了《2025 年度"提质增效重回报"行动方案》，本方案已经公司四届董事会第二十三次会 议审议通过，具体如下： 一、聚焦主业发展，提升经营质量 公司始终聚焦于药用玻璃管制瓶等药用包装材料的研发、生产和销售，公司 是国内药用玻璃行业中同时具备技术、人才、自动化生产及完整的"拉管--制瓶 —制盖"一体化生产企业，具备长期在该领域发展的核心竞争力。公 ...

持续赢得消费者信赖背后，是海天始终践行的"用户至上"理念。海天以创新驱动，精准回应市场升级需求，目前已建立起覆盖酱油、蚝油、酱料等超1000个 SKU的产品矩阵，横跨全价格带与全功能带，有效穿透消费圈层，精准适配全国不同区域和不同饮食习惯的多元需求。 转自：海天味业 【新华企业资讯8月22日】8月21日，Worldpanel消费者指数（在中国隶属于CTR）发布《2025品牌足迹报告》。调味品行业领军企业海天味业再次荣登中国 消费者十大首选品牌榜单，位列总榜第四位。海天已连续11年登上该榜，8年蝉联前四位，并稳居调味品首位。 2025年报告显示，海天"消费者触及数"达7.54亿，较上年增长2160万，并连续三年保持超过80%的高渗透率，显著领先于行业平均水平。这也意味着，平均 每10个中国家庭就有8个以上选择海天。 在持续巩固酱油、蚝油、酱料等核心品类优势的基础上，海天积极捕捉消费趋势变化，不断推陈出新。为顺应健康化潮流，企业陆续推出有机系列、减盐减 糖、铁强化、无麸质等健康类产品累计达1200余款。这些产品在保留传统中式风味的同时，切实契合低糖、低盐、低脂等现代健康诉求，获得市场广泛认 可。特别是2024年上 ...

Core Insights - The company reported a revenue of 1.79 billion yuan in the first half of 2025, with a net profit of 108 million yuan, and total assets of 6.037 billion yuan as of June 30, 2025 [1][2] Group 1: Cosmetics Business - The cosmetics segment generated a revenue of 1.094 billion yuan in the first half of 2025, with the Yilian brand achieving 554 million yuan, reflecting a year-on-year growth of 23.78% [2] - The Yilian brand launched a global spokesperson, Zhang Linghe, and held a summer spray festival, with spray product line sales reaching 482 million yuan, an increase of 43% [2] - The Aier Doctor brand reported a revenue of 451 million yuan, with new products like the 287 mask and 287 lotion, generating nearly 10 million yuan in sales within two months of launch [2] Group 2: Pharmaceutical Business - The pharmaceutical segment achieved a revenue of 207 million yuan, expanding its client base by over 200 hospitals and OTC customers [2] - Key products include children's flu medication and a popular pain relief product recognized at the Wuzhen Health Conference [2] - The company is actively developing food-medicine integration standards and collaborating with major clients to enhance raw material supply [2] Group 3: Raw Materials and Additives - The raw materials and additives segment reported a revenue of 179 million yuan, with hyaluronic acid sales reaching 116 million yuan, a year-on-year increase of 23.4% [3] - Medical-grade hyaluronic acid sales surged by 287.3%, totaling 16.08 million yuan [3] - The overall gross margin for the hyaluronic acid business improved to 47.1%, up by 8.5 percentage points [3] Group 4: Innovation and R&D - The company launched over 80 new products in the cosmetics sector, including the Aier Doctor 287 mask and Yilian purple essence water [3] - The company introduced a pioneering transdermal collagen technology, enhancing skin penetration by 27.5 times [3] - The company has made significant progress in medical device registrations and drug development, including obtaining production licenses for various products [3]

中新网杭州8月21日电 (潘沁文)8月20日至21日，2025CBE杭州国际美容博览会在浙江杭州举行。此次大 会汇聚来自20个国家和地区的超1000家化妆品产业链相关展商，共襄驱动美妆经济增长、引领产业未来 生态的盛会。 "中国文化正在以鲜活的创新形式走向世界，中国消费品在全球市场日益增长的影响力让我们相信，坚 持创新驱动，中国美妆必将成为下一个风靡全球的中国'金名片'。"侯军呈说道。 美妆生态大会现场。潘沁文 摄 此外，本次展会还值得关注的是，泰国美妆健康产品组团亮相，19家泰国企业迎来新品首发，令不少客 商驻足。 "近年来泰国美妆对华出口持续增长，中国消费者对'泰国制造'的信任度显著提升。"泰国驻上海总领事 馆商务处商务领事陈世光表示，期待通过本次展会让更多优质泰国品牌走进中国市场，并推动中泰企业 技术合作与渠道对接。(完) 创新也是浙江美妆发展的重要关键词。近年来，该省不断深化监管创新，通过制定实施"浙江美妆18 条"、深化备案改革、推进柔性执法等激发产业创新活力。今年上半年，浙江省新原料备案同比增长 100%；化妆品出口额66.42亿元，同比增长12.4%，占全国化妆品出口总额的25.74%，居全国第 ...

Core Viewpoint - The company has demonstrated strong performance in a challenging market environment, achieving growth in both revenue and net profit while making significant advancements in key areas [1][2]. Financial Performance - The company reported a revenue of 2.168 billion yuan, representing a year-on-year increase of 7.72% - The net profit attributable to shareholders reached 143 million yuan, up by 4.18% - Sales volume of the main adhesive products reached approximately 160,000 tons, marking a growth of 25.56% [2]. Business Segments and Innovations - In the automotive sector, the company capitalized on the rapid growth of the new energy vehicle market, with lithium battery adhesive product sales doubling and negative electrode adhesive PAA achieving full production and sales - The sales of thermal conductive structural adhesives surged year-on-year, showcasing the company's strong competitive edge in new energy materials [3]. - In the electronics sector, the company successfully launched several high-end chip packaging materials, entering mass production with clients, thereby solidifying its leading position in the electronic adhesive market [3]. - In the photovoltaic sector, the company implemented effective measures to address industry challenges, resulting in a year-on-year sales increase of approximately 9.3% for photovoltaic adhesives, maintaining a leading market share [3]. Research and Development - The company increased its R&D investment to approximately 85.2243 million yuan, a year-on-year growth of 17.39% - It initiated 22 key R&D projects covering high-end fields such as chip thermal adhesives and magnetic adhesives, with 14 projects already in mass production, supporting future revenue growth [4]. - The construction of a project with an annual production capacity of 36,000 tons for lithium battery negative electrode adhesives is progressing steadily, enhancing production capacity and market responsiveness [4]. Future Outlook - The company is optimistic about the industry's prospects, anticipating new growth opportunities in the adhesive sector supported by national policies and upgrades in downstream industry structures - It plans to continue its innovation-driven development strategy, increasing R&D investments in high-end electronics, new energy vehicles, and green packaging to enhance product value and technology content [5]. - The company aims to deepen collaborations with strategic major clients, expand into emerging markets, and improve market share, striving for higher quality development [5]. - The company is positioned to lead and drive the development of the adhesive and new materials sector, leveraging its advantages in technology R&D, brand influence, and customer resources [5].

Core Insights - The article emphasizes the importance of talent in driving innovation and economic development in Hangzhou, particularly in the context of the West Science and Technology Innovation Corridor [5][6][11] - It highlights the unique talent attraction strategies employed by the corridor, including financial incentives and flexible talent recognition policies [7][10][11] Group 1: Talent Attraction Strategies - The West Science and Technology Innovation Corridor has become a hub for young talent, with over 80,000 individuals under 35 years old, representing 1/3 of the province's national and provincial-level leading talents [6][11] - The corridor offers significant financial incentives, such as a 400,000 yuan subsidy for postdoctoral researchers, which is seen as a crucial factor in retaining talent [7][10] - The introduction of a talent self-recognition policy allows employers to identify and certify high-level talents, giving them more control over their hiring processes [7][8] Group 2: Ecosystem and Quality of Life - The article discusses how the quality of life in Hangzhou, including its natural beauty and cultural heritage, plays a significant role in attracting talent [9][10] - The corridor's focus on creating a supportive ecosystem for innovation, including efficient government services and a vibrant industry environment, enhances its appeal to professionals [10][11] - The shift from a policy-driven approach to a comprehensive ecosystem approach reflects a broader trend in urban talent competition, emphasizing the importance of a nurturing environment for talent retention and growth [11][12]